FOXO transcription factors in non-alcoholic fatty liver disease

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disorder that begins with simple hepatic steatosis and progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even liver cancer. As the global prevalence of NAFLD rises, it is increasingly important that we understand its pathogenesis and develop effective therapies for this chronic disease. Forkhead box O (FOXO) transcription factors are key downstream regulators in the insulin/insulin-like growth factor 1 (IGF1) signaling pathway, and have been implicated in a range of cellular functions including the regulation of glucose, triglyceride, and cholesterol homeostasis. The role of FOXOs in the modulation of immune response and inflammation is complex, with reports of both pro- and anti-inflammatory effects. FOXOs are reported to protect against hepatic fibrosis by inhibiting proliferation and transdifferentiation of hepatic stellate cells. Mice that are deficient in hepatic FOXOs are more susceptible to non-alcoholic steatohepatitis than wild-type controls. In summary, FOXOs play a critical role in maintaining metabolic and cellular homeostasis in the liver, and dysregulation of FOXOs may be involved in the NAFLD development.

Original languageEnglish (US)
Pages (from-to)168-173
Number of pages6
JournalLiver Research
Volume1
Issue number3
DOIs
StatePublished - Sep 2017

Fingerprint

Forkhead Transcription Factors
Liver
Fibrosis
Fatty Liver
Homeostasis
Hepatic Stellate Cells
Somatomedins
Liver Neoplasms
Triglycerides
Chronic Disease
Anti-Inflammatory Agents
Cholesterol
Non-alcoholic Fatty Liver Disease
Insulin
Inflammation
Glucose

Keywords

  • Fibrosis
  • Forkhead box O (FOXO)
  • Inflammation
  • Insulin-like growth factor 1 (IGF1)
  • Non-alcoholic fatty liver disease (NAFLD)
  • Steatosis

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

FOXO transcription factors in non-alcoholic fatty liver disease. / Dong, X. Charlie.

In: Liver Research, Vol. 1, No. 3, 09.2017, p. 168-173.

Research output: Contribution to journalReview article

@article{299607089f1c43f283a2e1a7f1c1498f,
title = "FOXO transcription factors in non-alcoholic fatty liver disease",
abstract = "Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disorder that begins with simple hepatic steatosis and progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even liver cancer. As the global prevalence of NAFLD rises, it is increasingly important that we understand its pathogenesis and develop effective therapies for this chronic disease. Forkhead box O (FOXO) transcription factors are key downstream regulators in the insulin/insulin-like growth factor 1 (IGF1) signaling pathway, and have been implicated in a range of cellular functions including the regulation of glucose, triglyceride, and cholesterol homeostasis. The role of FOXOs in the modulation of immune response and inflammation is complex, with reports of both pro- and anti-inflammatory effects. FOXOs are reported to protect against hepatic fibrosis by inhibiting proliferation and transdifferentiation of hepatic stellate cells. Mice that are deficient in hepatic FOXOs are more susceptible to non-alcoholic steatohepatitis than wild-type controls. In summary, FOXOs play a critical role in maintaining metabolic and cellular homeostasis in the liver, and dysregulation of FOXOs may be involved in the NAFLD development.",
keywords = "Fibrosis, Forkhead box O (FOXO), Inflammation, Insulin-like growth factor 1 (IGF1), Non-alcoholic fatty liver disease (NAFLD), Steatosis",
author = "Dong, {X. Charlie}",
year = "2017",
month = "9",
doi = "10.1016/j.livres.2017.11.004",
language = "English (US)",
volume = "1",
pages = "168--173",
journal = "Liver Research",
issn = "2542-5684",
number = "3",

}

TY - JOUR

T1 - FOXO transcription factors in non-alcoholic fatty liver disease

AU - Dong, X. Charlie

PY - 2017/9

Y1 - 2017/9

N2 - Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disorder that begins with simple hepatic steatosis and progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even liver cancer. As the global prevalence of NAFLD rises, it is increasingly important that we understand its pathogenesis and develop effective therapies for this chronic disease. Forkhead box O (FOXO) transcription factors are key downstream regulators in the insulin/insulin-like growth factor 1 (IGF1) signaling pathway, and have been implicated in a range of cellular functions including the regulation of glucose, triglyceride, and cholesterol homeostasis. The role of FOXOs in the modulation of immune response and inflammation is complex, with reports of both pro- and anti-inflammatory effects. FOXOs are reported to protect against hepatic fibrosis by inhibiting proliferation and transdifferentiation of hepatic stellate cells. Mice that are deficient in hepatic FOXOs are more susceptible to non-alcoholic steatohepatitis than wild-type controls. In summary, FOXOs play a critical role in maintaining metabolic and cellular homeostasis in the liver, and dysregulation of FOXOs may be involved in the NAFLD development.

AB - Non-alcoholic fatty liver disease (NAFLD) is a chronic progressive liver disorder that begins with simple hepatic steatosis and progresses to non-alcoholic steatohepatitis, fibrosis, cirrhosis, and even liver cancer. As the global prevalence of NAFLD rises, it is increasingly important that we understand its pathogenesis and develop effective therapies for this chronic disease. Forkhead box O (FOXO) transcription factors are key downstream regulators in the insulin/insulin-like growth factor 1 (IGF1) signaling pathway, and have been implicated in a range of cellular functions including the regulation of glucose, triglyceride, and cholesterol homeostasis. The role of FOXOs in the modulation of immune response and inflammation is complex, with reports of both pro- and anti-inflammatory effects. FOXOs are reported to protect against hepatic fibrosis by inhibiting proliferation and transdifferentiation of hepatic stellate cells. Mice that are deficient in hepatic FOXOs are more susceptible to non-alcoholic steatohepatitis than wild-type controls. In summary, FOXOs play a critical role in maintaining metabolic and cellular homeostasis in the liver, and dysregulation of FOXOs may be involved in the NAFLD development.

KW - Fibrosis

KW - Forkhead box O (FOXO)

KW - Inflammation

KW - Insulin-like growth factor 1 (IGF1)

KW - Non-alcoholic fatty liver disease (NAFLD)

KW - Steatosis

UR - http://www.scopus.com/inward/record.url?scp=85060348902&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060348902&partnerID=8YFLogxK

U2 - 10.1016/j.livres.2017.11.004

DO - 10.1016/j.livres.2017.11.004

M3 - Review article

AN - SCOPUS:85060348902

VL - 1

SP - 168

EP - 173

JO - Liver Research

JF - Liver Research

SN - 2542-5684

IS - 3

ER -